Top 2010 Established Biotech Stock Picks for Upside (MNKD, THRX, DNDN, INCY, ILMN, ALNY, GILD, SVNT, AMGN, ONXX, PDLI, OSIP, CELG)

January 4, 2010 · Filed Under Cancer, Diabetes, Financial, M&A, R&D, dendreon, fda, flu, genomics, multiple sclerosis, obesity, stem cells · 1 Comment 

BioHealthInvestor.com wanted to put together a list of key biotech and BioHealth-related stocks that had the most upside for 2010 according to consensus analyst price targets.  This is of course no exact science for many reasons, but getting a lot of consensus price targets together is often a sign of at least where to start when looking for upward price targets in stocks.  And we all know that BioHealth and biotech stocks often offer the upside of the century as these companies all hold a bit of your own personal lottery ticket in all of their share prices.

After taking a look at our normal universe of biotech and biohealth related stocks. it was obvious that MannKind Corp. (NASDAQ: MNKD) still has the most upside from the consensus price targets IF it is hit.  Then in order of expected share price appreciation comes Theravance Inc. (NASDAQ: THRX), Dendreon Corp. (NASDAQ: DNDN), Incyte Corporation (NASDAQ: INCY), and then came Illumina Inc. (NASDAQ: ILMN), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Gilead Sciences Inc. (NASDAQ: GILD).

The stocks above all had upside of over 25%.  The other stocks here are the ‘lower rung’ of upside expectations but are all still offering over 20% upside to the consensus analyst price targets (again IF they are hit).  Of the 13 stocks with markets caps of $750 million (or almost $750 million) which we cover, these still had upside of over 20% except a few: Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), Amgen Inc. (NASDAQ: AMGN), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), PDL BioPharma, Inc. (NASDAQ: PDLI), OSI Pharmaceuticals Inc. (NASDAQ: OSIP), and Celgene Corporation (NASDAQ: CELG).
Read more

Tags: , , , , , , , , , , , ,

Short Sellers Lighten Up on Major Biotechs in May

June 11, 2008 · Filed Under General · Comments Off 

We ran the short selling report that just came out on major NASDAQ biotech stocks to see what the change in short selling was.  Interestingly enough, in almost all of the major and large US biotechs traded on NASDAQ.

STOCK (Ticker)                               MAY 30     MAY 15          CHANGE
Amgen Inc. (AMGN)                   22,678,517   24,778,770   -8.48%
Biogen Idec Inc. (BIIB)                 6,346,464    6,788,432     -6.51%
Celgene Corporation (CELG)      13,775,373   16,336,232   -15.68%
Genzyme Corporation (GENZ)      5,684,945    5,621,969    +1.12%
Gilead Sciences, Inc. (GILD)       32,478,444   32,690,603   -0.65
ImClone Systems Inc. (IMCL)       7,149,395    7,664,009    -6.71%

And below you can see the short selling changes on some of the smaller biotechs that are still rather active in daily trading volume.  The results below are more mixed than they are in the major biotechs.

STOCK (Ticker)                                        MAY 30     MAY 15          CHANGE
Amylin Pharmaceuticals, Inc. (AMLN)  23,855,471   23,642,854     +0.90%
Cell Genesys, Inc. (CEGE)                     16,931,592   17,222,281     -1.69%
Dendreon Corporation (DNDN)            31,117,812  30,728,499     +1.27%
Illumina, Inc. (ILMN)                             12,239,553  11,902,877     +2.83
Invitrogen Corporation (IVGN)              9,125,954    9,340,210      -2.29%
Medarex, Inc.  (MEDX)                          21,837,573  19,682,828     +10.95%

Jon C. Ogg
June 11, 2008

Tags: , , , , , , , , , , , , ,

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed